Stuart A. Randle - Jan 4, 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc. (CMRA)

Role
Director
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Stock symbol
CMRA
Transactions as of
Jan 4, 2023
Transactions value $
$49,999
Form type
4
Date filed
1/6/2023, 03:14 PM
Previous filing
Feb 14, 2023
Next filing
Feb 16, 2023
SEC
View on sec.gov
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CMRA Common Stock Award $41.6K +33.8K +388.94% $1.23 42.5K Jan 4, 2023 Direct F1
holding CMRA Common Stock 31.6K Jan 4, 2023 The Stuart A. Randle Trust of 1998 F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMRA Warrants (right to buy) Award $8.45K +33.8K $0.25 33.8K Jan 4, 2023 Common Stock 67.6K $1.23 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 33,783 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules.
F2 These shares are owned directly by The Stuart A. Randle Trust of 1998 (the "Trust"). Mr. Stuart Randle is the trustee of the Trust, and may be deemed to be a beneficial owner of these shares.
F3 The exercisability of the Warrants is subject to a 4.99% beneficial ownership limitation.